{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:33:11Z","timestamp":1792110791072,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Fosphenytoin (FOS) is a prodrug of phenytoin (PHT) with a metabolism that exhibits Michaelis\u2013Menten-type kinetics. Genetic polymorphisms of the metabolic enzymes of PHT make it challenging to predict its plasma concentrations. High plasma PHT concentrations are typically problematic, and several causes have been elucidated. In contrast, cases of patients with low PHT plasma concentrations that did not increase despite the administration of appropriate PHT doses have been reported, and the causes may include changes in plasma protein-binding rates, genetic mutations, and concomitant use of drugs that induce liver enzymes; however, even these factors do not explain the low PHT plasma concentrations in some cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We encountered the case of a patient with plasma PHT concentrations that were continuously\u2009&lt;\u20090.7\u00a0\u00b5g\/mL after daily use of FOS for seizures that occurred after cardiopulmonary arrest. We analyzed the protein-unbound fraction, urinary metabolites, and related genes to investigate the cause. False negatives due to the measurement method, errors in dosage and administration method, and increased excretion of PHT were excluded. Hepatic metabolic activity of PHT increased to 4.6\u20136.1 times the normal level. The S\/R ratio of 5-(p-hydroxyphenyl)-5-phenylhydantoin-glucuronide, a major PHT metabolite, was normal at 15.2, suggesting increased activities of CYP2C9 and CYP2C19. Furthermore, the protein-unbound fraction of PHT was 5.2\u20136.9%, <jats:italic>CYP2C19<\/jats:italic><jats:sup><jats:italic>*<\/jats:italic><\/jats:sup><jats:italic>17<\/jats:italic> was wild type, and there was no concomitant drug use to induce both enzymes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The low PHT plasma concentration in this patient was found to be caused by increased hepatic metabolic activity that could not be explained by known factors. Careful monitoring is necessary to consider the possibility of increased hepatic metabolic activity in similar cases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40780-024-00374-6","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T12:02:23Z","timestamp":1724846543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient resuscitated after cardiopulmonary arrest exhibits abnormally increased phenytoin metabolic rate due to unknown factors: a case report"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8335-313X","authenticated-orcid":false,"given":"Ayumu","family":"Nagamine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Yashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohiro","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Obayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koujirou","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"374_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00003088-200342010-00002","volume":"42","author":"JH Fischer","year":"2003","unstructured":"Fischer JH, Patel TV, Fischer PA. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet. 2003;42:33\u201358.","journal-title":"Clin Pharmacokinet"},{"key":"374_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/j.1552-4604.1988.tb03124.x","volume":"28","author":"N Gerber","year":"1988","unstructured":"Gerber N, Mays DC, Donn KH, Laddu A, Guthrie RM, Turlapaty P, et al. Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. J Clin Pharmacol. 1988;28:1023\u201332.","journal-title":"J Clin Pharmacol"},{"key":"374_CR3","first-page":"1239","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies Epilepsia. 2008;49:1239\u201376.","journal-title":"ILAE Commission on Therapeutic Strategies Epilepsia"},{"key":"374_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2006.08.026","volume":"377","author":"A Dasgupta","year":"2007","unstructured":"Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta. 2007;377:1\u201313.","journal-title":"Clin Chim Acta"},{"key":"374_CR5","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1248\/bpb.19.444","volume":"19","author":"A Odani","year":"1996","unstructured":"Odani A, Hashimoto Y, Takayanagi K, Otsuki Y, Koue T, Takano M, et al. Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. Biol Pharm Bull. 1996;19:444\u20138.","journal-title":"Biol Pharm Bull"},{"key":"374_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00613423","volume":"9","author":"J Koch-Weser","year":"1975","unstructured":"Koch-Weser J. The serum level approach to individualization of drug dosage. Eur J Clin Pharmacol. 1975;9:1\u20138.","journal-title":"Eur J Clin Pharmacol"},{"key":"374_CR7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/phar.2273","volume":"39","author":"MC Montgomery","year":"2019","unstructured":"Montgomery MC, Chou JW, McPharlin TO, Baird GS, Anderson GD. Predicting unbound phenytoin concentrations: effects of albumin concentration and kidney dysfunction. Pharmacotherapy. 2019;39:756\u201366.","journal-title":"Pharmacotherapy"},{"key":"374_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1528-1157.1994.tb02922.x","volume":"35","author":"T Tomson","year":"1994","unstructured":"Tomson T, Lindbom U, Ekqvist B, Sundqvist A. Disposition of carbamazepine and phenytoin in pregnancy. Epilepsia. 1994;35:131\u20135.","journal-title":"Epilepsia"},{"key":"374_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/00007691-198103000-00013","volume":"3","author":"D Haidukewych","year":"1981","unstructured":"Haidukewych D, Rodin EA. Serial free and plasma valproic acid and phenytoin monitoring and drug interactions. Ther Drug Monit. 1981;3:303\u20137.","journal-title":"Ther Drug Monit"},{"key":"374_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/BF01493371","volume":"53","author":"R Gugler","year":"1975","unstructured":"Gugler R, Azarnoff DL, Shoeman DW. Diphenylhydantoin: correlation between protein binding and albumin concentration. Klin Wochenschr. 1975;53:445\u20136.","journal-title":"Klin Wochenschr"},{"key":"374_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1056\/NEJM197107292850506","volume":"285","author":"MM Reidenberg","year":"1971","unstructured":"Reidenberg MM, Odar-Cederl\u00f6f I, von Bahr C, Borg\u00e5 O, Sj\u00f6qvist F. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med. 1971;285:264\u20137.","journal-title":"N Engl J Med"},{"key":"374_CR12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","volume":"121","author":"D Sibbing","year":"2010","unstructured":"Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121:512\u20138.","journal-title":"Circulation"},{"key":"374_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","volume":"2","author":"PN Patsalos","year":"2003","unstructured":"Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2:347\u201356.","journal-title":"Lancet Neurol"},{"key":"374_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","volume":"2","author":"PN Patsalos","year":"2003","unstructured":"Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2:473\u201381.","journal-title":"Lancet Neurol"},{"key":"374_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s13318-012-0105-x","volume":"38","author":"Y Inoue","year":"2013","unstructured":"Inoue Y, Usui N, Hiroki T, Shimizu K, Kobayashi S, Shimasaki S. Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers. Eur J Drug Metab Pharmacokinet. 2013;38:139\u201348.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"374_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/00008571-200110000-00005","volume":"11","author":"Y Caraco","year":"2001","unstructured":"Caraco Y, Muszkat M, Wood AJ. Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. Pharmacogenetics. 2001;11:587\u201396.","journal-title":"Pharmacogenetics"},{"key":"374_CR17","first-page":"1401","volume":"24","author":"M Bajpai","year":"1996","unstructured":"Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos. 1996;24:1401\u20133.","journal-title":"Drug Metab Dispos"},{"key":"374_CR18","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/0006-291X(91)91680-B","volume":"175","author":"ME Veronese","year":"1991","unstructured":"Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun. 1991;175:1112\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"374_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1365-2710.2006.00712.x","volume":"31","author":"E Yukawa","year":"2006","unstructured":"Yukawa E, Mamiya K. Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using non-linear mixed effects model approach. J Clin Pharm Ther. 2006;31:275\u201382.","journal-title":"J Clin Pharm Ther"},{"key":"374_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.eplepsyres.2006.05.015","volume":"71","author":"UA Argikar","year":"2006","unstructured":"Argikar UA, Cloyd JC, Birnbaum AK, Leppik IE, Conway J, Kshirsagar S, et al. Paradoxical urinary phenytoin metabolite (S)\/(R) ratios in CYP2C19* 1\/*2 patients. Epilepsy Res. 2006;71:54\u201363.","journal-title":"Epilepsy Res"},{"key":"374_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.resuscitation.2016.01.006","volume":"103","author":"MA Peberdy","year":"2016","unstructured":"Peberdy MA, Andersen LW, Abbate A, Thacker LR, Gaieski D, Abella BS, et al. Inflammatory markers following resuscitation from out-of-hospital cardiac arrest-A prospective multicenter observational study. Resuscitation. 2016;103:117\u201324.","journal-title":"Resuscitation"},{"key":"374_CR22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/clpt.2014.143","volume":"96","author":"RD Harvey","year":"2014","unstructured":"Harvey RD, Morgan ET. Cancer, inflammation, and therapy: effects on cytochrome P450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther. 2014;96:449\u201357.","journal-title":"Clin Pharmacol Ther"},{"key":"374_CR23","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1097\/01.CCM.0000281517.97507.6E","volume":"35","author":"MA Tortorici","year":"2007","unstructured":"Tortorici MA, Kochanek PM, Poloyac SM. Effects of hypothermia on drug disposition, metabolism, and response: a focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system. Crit Care Med. 2007;35:2196\u2013204.","journal-title":"Crit Care Med"},{"key":"374_CR24","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/FTD.0000000000000521","volume":"40","author":"Y Ohno","year":"2018","unstructured":"Ohno Y, Niwa T, Hirai K, Suzuki K, Yamada Y, Hayashi Y, et al. Time-dependent decline in serum phenytoin concentration with heightened convulsive seizure risk by prolonged administration of fosphenytoin in Japanese: a retrospective study. Ther Drug Monit. 2018;40:507\u201311.","journal-title":"Ther Drug Monit"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-024-00374-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-024-00374-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-024-00374-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T12:07:08Z","timestamp":1724846828000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-024-00374-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["374"],"URL":"https:\/\/doi.org\/10.1186\/s40780-024-00374-6","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since this is a case report, ethical approval was deemed unnecessary by the Medical Ethics Committee of Gunma University. Informed consent was obtained from the patient\u2019s family.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for the publication of this case was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}